Tom Robinson, vice president of global access at JDRF, explains how to navigate the Type 1 Diabetes (T1D) Index and what data can be pulled from it.
The Type 1 Diabetes (T1D) Index, which was launched in September, provides payers with a good foundation for value-based health care, said Tom Robinson, vice president of global access at JDRF.
Transcript
How can someone navigate the T1D Index?
The simplest thing is to just go to T1Dindex.org and look at the world map there, maybe compare a few countries that are of interest, and then dive into the one that you care most about. Then it takes you through the story of that country and how type 1 looks today—the growth story, the loss and the burden, and what can be done to address that burden. From there, if you want to go deeper, you can dive into the Lancet paper, or there's a dashboard tool, or the codebase is available open source. So there's a lot of layers to peel beyond that, but starting point is just that T1Dindex.org website.
What information can patients, providers, and payers gain from the T1D Index?
The index is this incredibly rich simulation of each country, but there are 3 main numbers that we draw out of it. The first is how many people are living with type 1. The second is how many people should be alive with type 1 if they received really good care. The third is how many healthy life-years are lost to the average person who develops type 1.
And then for each of those numbers, we also look at how interventions can improve care and change the numbers and change the story of type 1 in that country. And I think how you engage with that is really different depending on who you are. If you're a person living with type 1, you might dive into, "Oh, wow, each extra test trip could add 4 hours to my life. Maybe I'm going to think about marching into that local pharmacy and making sure they stock the test trips." For a provider, they might look at some of the incidence rates and ask, "Hey, are we catching everyone?" or look at the growth estimates and say, "Are we prepared for this? Do we need to think about evolving our model for this rapid growth in type 1?"
For a payer, government, or insurer, you've got some good foundations, frankly, for value-based health care in this model. You can bring your cost models, the epidemiology we've done, and then drop out things like dollars per life-year or get under the hood about complications modeling and look at lifetime health care costs and so forth. Some of this is readily available on the website, some you need to kind of start using the interactive tools to really get to grips with and get the full value out of, but there's a lot of depth behind that kind of initial public face.
HS Treatment Goals: Better Quality of Life, Not Just Control
January 3rd 2025For part 3 of our discussion with Chris Sayed, MD, we tackle several important topics in the hidradenitis suppurative (HS) and inflammatory disease space: patient quality of life, medication and treatment goals, and the possibility of a cure.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Dr Yehuda Handelsman: DCRM Guidelines Are Shaping Integrated, Global CRM Care
January 3rd 2025In part 2 of our interview, Yehuda Handelsman, MD, discusses how cardiorenalmetabolic (CRM) disease management is advancing with the 2022 Diabetes, Cardiorenal, and Metabolic (DCRM) multispecialty practice recommendations and the updated DCRM 2.0 guidelines.
Read More
Stripped of Fucose, Powerful Monoclonal Antibody Shows Promising Results in MDS Dosing Study
January 2nd 2025Nicole Grieselhuber, MD, PhD, of The Ohio State University, discusses results from Part D of a dosing study involving patients with previously untreated higher-risk myelodysplastic syndrome (MDS) who were treated with a combination of SEA-CD70 and azacitidine.
Read More